Table 3.
Clinicopathology features of ADAMTS9 methylation in breast cancer
| Clinicopathological features | Number (n = 219) | ADAMTS9 promoter methylation status | P value | |
|---|---|---|---|---|
| Methylated | Unmethylated | |||
| Age | 0.999 | |||
| ≤40 | 32 | 19 (59.4%) | 13 (40.6%) | |
| >40 | 187 | 111 (59.4%) | 76 (40.6%) | |
| Grade | 0.312 | |||
| 1 | 13 | 8 (61.5%) | 5 (38.5%) | |
| 2 | 149 | 91 (61.1%) | 58 (38.9%) | |
| 3 | 24 | 10 (41.7%) | 14 (58.3%) | |
| unknown | 33 | 21 (63.6%) | 12 (36.4%) | |
| Tumour size | 0.079 | |||
| ≤2.0 cm | 99 | 59 (59.6%) | 40 (40.4%) | |
| >2.0 cm ≤ 5.0 cm | 99 | 63 (63.6%) | 36 (36.4%) | |
| >5.0 cm | 18 | 8 (44.4) | 10 (55.6%) | |
| unknown | 3 | 0 (0.0%) | 3 (100.0%) | |
| Lymph node metastasis | 0.446 | |||
| Positive | 98 | 54 (55.1%) | 44 (44.9%) | |
| Negative | 117 | 74 (63.2%) | 43 (36.8%) | |
| unknown | 4 | 2 (50.0%) | 2 (50.0%) | |
| ER status | 0.943 | |||
| Positive | 122 | 73 (59.8%) | 49 (40.2%) | |
| Negative | 86 | 51 (59.3%) | 35 (40.7%) | |
| unknown | 11 | 6 (54.5%) | 5 (45.5%) | |
| PR status | 0.939 | |||
| Positive | 98 | 58 (59.2%) | 40 (40.8%) | |
| Negative | 110 | 66 (60.0%) | 44 (40.0%) | |
| unknown | 11 | 6 (54.5%) | 5 (45.5%) | |
| HER2 status | 0.030 | |||
| Positive | 13 | 7 (53.8%) | 6 (46.2%) | |
| Negative | 89 | 44 (49.4%) | 45 (50.6%) | |
| unknown | 117 | 79 (67.5%) | 38 (32.5%) | |
| p53 expression | 0.535 | |||
| Positive | 113 | 67 (59.3%) | 46 (40.7%) | |
| Negative | 83 | 47 (56.6%) | 36 (43.4%) | |
| unknown | 23 | 16 (69.6%) | 7 (30.4%) | |